Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab, tremelimumab, and enfortumab vedotin for cisplatin-ineligible or cisplatin-refusing muscle-invasive bladder cancer
NL-OMON59851Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of durvalumab, tremelimumab and enfortumab vedotin in bladder cancer and transitional cell carcinoma (TCC) (3 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability in safety run-in and Event-free survival. Started Nov 2021; status: active, not recruiting.
02
Drugs
durvalumabtremelimumabenfortumab vedotin
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON59851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59851.